New England Asset Management Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 15.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,632 shares of the company’s stock after buying an additional 3,382 shares during the quarter. New England Asset Management Inc.’s holdings in Johnson & Johnson were worth $3,193,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in JNJ. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares in the last quarter. Taylor Wealth Management Partners boosted its stake in Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares in the last quarter. Foundation Resource Management Inc. acquired a new position in Johnson & Johnson in the first quarter worth $204,000. Finally, Arbor Investment Advisors LLC acquired a new position in Johnson & Johnson in the first quarter worth $215,000. 66.00% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE JNJ) traded up 1.49% during midday trading on Monday, reaching $132.93. The company had a trading volume of 2,101,231 shares. The company has a market capitalization of $356.78 billion, a PE ratio of 22.49 and a beta of 0.79. The stock has a 50-day moving average price of $132.39 and a 200 day moving average price of $128.88. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.74 earnings per share. Equities analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

A number of equities analysts have commented on JNJ shares. J P Morgan Chase & Co raised Johnson & Johnson from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $123.64 to $140.00 in a research note on Monday, May 15th. UBS AG reissued a “buy” rating and issued a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 price objective on the stock. in a research note on Monday, May 15th. Finally, BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $134.60.

ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Position Increased by New England Asset Management Inc.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/11/johnson-johnson-jnj-position-increased-by-new-england-asset-management-inc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.